- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Organ-on-a-Chip Market Size, Share & Forecast | CAGR 33.4%
Global Organ-on-a-Chip Market Size, Share Analysis By Offering (Devices, Consumables, Software, Microfluidic, Media, Sensors, R&D), By Organ (Liver, Lung, Heart, Kidney, Brain, Gut, Skin, Tumor, Multi-Organ), By Application (Drug Discovery, Toxicity, Disease Modeling, Personalized Medicine, Cancer, Regenerative, Stem Cell), By End User (Pharma, Biotech, CROs, Academic, Hospitals, Med-Tech) Region & Key Players-Dynamics, Strategies, Trends & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
| USD 215.5 Million | USD 2,890 Million | 33.4% | North America, 45.0% |
The Organ-on-a-Chip Market was valued at USD 168.0 Million in 2024 and USD 215.5 Million in 2025. The market is projected to reach USD 2,890 Million by 2034, expanding at a CAGR of 33.4% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 2,674.5 Million over the analysis period. The Organ-on-a-Chip Market is being reset by regulatory action, capital flow into microphysiological systems, and the pharmaceutical industry's documented 90% clinical failure rate.
Organ-on-a-Chip Market Global Forecast to 2034 (USD)
CAGR OF
33.4%
Organ-on-a-Chip Market
Get more details on this report -
Demand momentum stems from the FDA Modernization Act 2.0 signed in December 2022, which removed the federal mandate for animal testing in new drug applications, and the FDA Modernization Act 3.0 passed by unanimous Senate consent in December 2025. The April 2025 FDA roadmap committed the agency to making animal studies the exception rather than the norm within three to five years. NIH ended exclusive funding for animal-only studies in July 2025, forcing investigators to integrate validated human-relevant methods into new proposals.
Microfluidics, induced pluripotent stem cell (iPSC) sourcing, and high-throughput automation are converging in the Organ-on-a-Chip Market. Emulate launched the AVA Emulation System in June 2025, running 96 organ-chip samples per cycle and cutting consumable costs four-fold. CN Bio Innovations introduced PhysioMimix Core in October 2025, supporting 288 simultaneous samples in a single benchtop microphysiological system. Multi-organ configurations linking liver, gut, kidney, and brain modules are shortening go/no-go decisions in early-stage pipelines.
North America dominated the Organ-on-a-Chip Market with a 45.0% revenue share in 2025, supported by the FDA ISTAND Pilot Program and the NIH TraCe MPS centers funded with USD 31 million across five years. Asia Pacific is the fastest-growing region with a forecast CAGR exceeding 36.0%, propelled by China's GB/T 44831-2024 skin-on-a-chip national standard published in November 2024. Europe benefits from the Dutch Centre for Animal-Free Biomedical Translation funded with EUR 124 million through the Dutch National Growth Fund.
Forward-looking demand through 2034 will be shaped by FDA qualification pathways for non-animal methods, expansion of pharma-CRO partnerships, and integration of organ-chip outputs with AI-driven analytics. Drug discovery applications will retain the largest application share, while disease modeling and personalized medicine segments record the fastest growth. The Organ-on-a-Chip Market is transitioning from academic novelty to procurement-grade preclinical infrastructure.
Market Definition & Scope
The Organ-on-a-Chip Market is defined as the commercial ecosystem for microengineered cell-culture devices that reproduce the architecture, fluid flow, mechanical forces, and physiological functions of human organs on microfluidic chips for use in drug discovery, toxicology, disease modeling, and personalized medicine. The market encompasses organ-chip platforms, consumables, software, and contract research services delivered to pharmaceutical, biotechnology, academic, contract research organization (CRO), and cosmetics end users.
This analysis includes single-organ and multi-organ microphysiological systems covering liver, lung, heart, kidney, brain, intestine, and skin models, plus body-on-a-chip configurations. It covers devices, consumables and reagents, software and analytical tools, and OOC-as-a-service contracts. Excluded: standalone organoid suspension cultures, classical 2D cell culture, in silico-only simulation platforms, and animal models. The Organ-on-a-Chip Market is a sub-segment of the broader microphysiological systems and 3D cell culture parent market.
Key Takeaways
- Market Growth: The Organ-on-a-Chip Market grew from USD 215.5 Million in 2025 toward USD 2,890 Million by 2034 at a CAGR of 33.4%, representing an absolute dollar opportunity of USD 2,674.5 Million.
- Segment Dominance (Offering): Devices and platforms held the largest offering share at 40.0% in 2025, valued at approximately USD 86.2 Million, driven by capital purchases of high-throughput instruments such as AVA and PhysioMimix Core.
- Segment Dominance (Application): Drug discovery and development held a 56.0% application share in 2025, generating USD 120.7 Million as pharmaceutical companies redirected screening budgets after the FDA April 2025 roadmap.
- Driver: Removal of mandatory animal testing under the FDA Modernization Act 2.0 plus the December 2025 passage of the Modernization Act 3.0 directly increased preclinical procurement of organ-chip platforms.
- Restraint: High development costs, lack of ISO standardization, and limited cellular diversity in current models constrain rapid scale-up and produce roughly 30 to 35% premium pricing versus 3D culture alternatives.
- Opportunity: Multi-organ and body-on-a-chip configurations represent a USD 230 Million incremental opportunity by 2034 as systemic toxicology screens replace siloed single-organ studies.
- Trend: AI-integrated organ-chip platforms are the dominant trend, with single seven-day AVA experiments generating over 30,000 imaging data points feeding predictive toxicity models.
- Regional: North America led with 45.0% share and USD 96.98 Million in revenue in 2025, anchored by the FDA ISTAND program and the NIH USD 31 Million TraCe MPS investment.
Key Insights Summary
- FDA ISTAND admission: Emulate's Liver-Chip S1 became the first organ-chip admitted to the FDA ISTAND Pilot Program in September 2024, demonstrating 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study.
- US drug failure economics: Roughly 90% of drug candidates that enter clinical trials fail, with 30% attributable to toxicity not detected by animal models, generating measurable demand for human-relevant preclinical platforms.
- NIH funding restriction: On July 7, 2025, the National Institutes of Health barred funding for animal-only studies, forcing every new grant proposal to integrate at least one validated New Approach Methodology such as organ-chip or organoid systems.
- Throughput leap: Emulate AVA, launched June 10, 2025, runs 96 independent organ-chip samples per cycle while reducing consumable spending four-fold and in-lab labor by 50% versus prior systems.
- Regulatory consolidation: The FDA Modernization Act 3.0, passed by unanimous Senate consent in December 2025, instructs the FDA to establish a formal qualification pathway for nonclinical methods including organ-chips.
- Chinese standardization: China issued GB/T 44831-2024, the world's first national standard for skin-on-a-chip technology, in November 2024, opening a regulated procurement channel for cosmetics and toxicology testing.
- Multi-organ benchmark: CN Bio's PhysioMimix Core, launched October 14, 2025, supports 288 simultaneous samples and is used by 16 of the leading global pharmaceutical companies according to the company's commercial disclosures.
Competitive Landscape Overview
The Organ-on-a-Chip Market is moderately consolidated. The top four players (Emulate, MIMETAS, CN Bio Innovations, and TissUse) accounted for an estimated 58% combined share in 2025, while the remainder is split across 30 active venture-backed companies. Competition is technology-led, anchored on chip biological fidelity, throughput per cycle, regulatory acceptance, and pharma reference customers.
Competitive pressure intensified in 2025 as Emulate launched AVA and CN Bio launched PhysioMimix Core within four months, both targeting the same high-throughput pharma procurement budget. Quris Technologies acquired Nortis in October 2024 to fold Kidney-on-Chip into its Bio-AI platform. Strategic alliances now matter as much as device specs: MIMETAS partnered into the EUR 124 Million Dutch CPBT consortium, while CN Bio entered a multi-application validation partnership with Pharmaron to embed PhysioMimix into CRO workflows.
Tracxn data published in October 2025 identified 35 active organ-on-chip companies, of which 28 had received institutional funding. The competitive matrix below benchmarks the ten most strategically active vendors against headquarters, market position, lead platform, geographic strength, and the most recent verified strategic move.
Competitive Landscape Matrix
| Company | Headquarters | Position | Key Platform | Geographic Strength | Recent Strategic Move |
| Emulate, Inc. | Boston, US | Leader | AVA Emulation System; Liver-Chip S1 | North America, EU pharma | Launched AVA high-throughput platform in June 2025 |
| MIMETAS B.V. | Oegstgeest, Netherlands | Leader | OrganoPlate; OrganoReady | Europe, North America | Joined EUR 124 million Dutch CPBT animal-free program |
| CN Bio Innovations Ltd | Cambridge, UK | Leader | PhysioMimix Core MPS | UK, US biopharma | Launched PhysioMimix Core in October 2025 |
| TissUse GmbH | Berlin, Germany | Leader | HUMIMIC multi-organ chip series | Europe DACH, Asia | Expanded HUMIMIC patents across 20-plus jurisdictions |
| InSphero AG | Schlieren, Switzerland | Challenger | Akura platform; 3D InSight microtissues | Europe, US biotech | Expanded oncology and metabolic disease 3D portfolio |
| Hesperos, Inc. | Orlando, US | Challenger | Human-on-a-Chip multi-organ system | US, Asia Pacific | Advanced rare-disease drug screening collaborations |
| AxoSim, Inc. | New Orleans, US | Niche Player | NerveSim; microBrain platform | US neurology research | Integrated Stemonix microBrain into neurology pipeline |
| BICO Group AB | Gothenburg, Sweden | Niche Player | Bioprinting + microfluidics portfolio | Europe, US, Asia | Expanded bioprinting-OOC convergence stack in 2025 |
| AlveoliX AG | Bern, Switzerland | Niche Player | AXLung-on-Chip | Europe respiratory R&D | Scaled lung-chip CRO services for inhaled drugs |
| Quris Technologies Ltd | Tel Aviv, Israel | Challenger | Bio-AI patient-on-chip platform | US, Israel | Acquired Nortis in October 2024 to add kidney chips |
Segmentation Analysis
The Organ-on-a-Chip Market is segmented across four primary dimensions: by offering, by organ type, by application, and by end user. Each dimension reflects a distinct procurement pattern, with offerings determined by capital versus operating budgets, organ types determined by therapeutic-area pipeline focus, applications determined by regulatory submission strategy, and end users determined by the in-house science capacity of buyers.
By Offering
Devices and platforms held the largest share of the offering segment at 40.0% in 2025, accounting for approximately USD 86.2 Million in revenue. Capital purchases of multi-channel benchtop instruments such as Emulate AVA and CN Bio PhysioMimix Core anchor this category. The segment benefits from longer hardware refresh cycles (five to seven years) and rising demand for higher chip-density configurations that increase throughput per square meter of laboratory floor space.
Services held a 35.0% share at USD 75.4 Million in 2025, growing fastest among the offerings as pharma R&D leaders outsource validation studies before moving organ-chip workflows in-house. CN Bio's enhanced DILI Contract Research Services launched in 2025 with rat (Sprague-Dawley) and dog (Beagle) primary liver MPS models illustrate the cross-species comparative analysis that pharma procurement teams use as part of their procurement checklist for organ-chip vendor selection. Consumables and reagents took 18.0% share at USD 38.8 Million, driven by recurring chip-array purchases that effectively annuitize device sales. Software and analytical tools captured 7.0% share at USD 15.1 Million, supported by AI-ready imaging output now standard on the latest generation.
By Organ Type
Liver-on-chip held the dominant organ type share at 32.0% in 2025, generating USD 69.0 Million, driven by drug-induced liver injury (DILI) screening and the FDA-validated 87% sensitivity benchmark from Emulate Liver-Chip S1. Lung-on-chip was the second-largest at 22.0%, used for respiratory toxicity, infectious disease, and aerosol delivery. Heart-on-chip captured 15.0% share and is forecast to record one of the fastest organ-specific CAGRs through 2034 due to cardiotoxicity demand from oncology pipelines.
Kidney-on-chip took 11.0% share at USD 23.7 Million, with MIMETAS expanding its OrganoPlate kidney module in August 2024 and the University of Washington TraCe MPS center anchoring NIH-funded kidney research. Brain-on-chip held 9.0%, supported by Wyss Institute immune-infiltrated organoid work. Multi-organ and body-on-chip captured 8.0% share at USD 17.2 Million; this sub-segment is forecast to record the highest CAGR among organ types as PhysioMimix Core and HUMIMIC platforms unlock systemic drug-response modeling. Skin-on-chip and other organs held 3.0% share, with regulatory tailwind from China's GB/T 44831-2024 standard.
By Application
Drug discovery and development dominated the application segment at 56.0% share in 2025, generating USD 120.7 Million in revenue. Pharmaceutical pipeline failure economics anchor demand: when 90% of clinical candidates fail (30% from toxicity), every preclinical signal that prevents a Phase 1 failure delivers a measurable ROI on organ-chip procurement. Toxicology research held 22.0% share at USD 47.4 Million, advancing as the FDA's April 2025 roadmap targeted monoclonal antibodies as the first therapeutic class to phase out compulsory animal studies.
Disease modeling captured 14.0% share at USD 30.2 Million in 2025 and is forecast to record one of the highest CAGRs through 2034 as patient-derived iPSC sourcing matures. Personalized medicine accounted for 5.0% share at USD 10.8 Million; the segment is anchored by Cedars-Sinai Heart-Chip cardiotoxicity work and Wyss Institute kidney organoid research. Other applications including regenerative medicine held 3.0% share. The drug discovery application share exceeded the toxicology share by 34 percentage points in 2025, highlighting the asymmetric procurement weight pharmaceutical pipelines apply to early-stage screening tools.
By End User
Pharmaceutical and biotechnology companies dominated the end-user segment at 67.0% share in 2025, generating USD 144.4 Million in revenue. Reference accounts include 16 of the top global pharmaceutical companies as PhysioMimix users per CN Bio's October 2025 disclosure, and Roche's adoption of MIMETAS technology in immuno-oncology programs. Procurement decisions inside large pharma now formally evaluate organ-chip ROI, regulatory acceptance trajectory, and integration timeline with existing automation infrastructure.
Academic and research institutes held 20.0% share at USD 43.1 Million, supported by NIH TraCe MPS centers at the University of Washington, University of Pittsburgh, University of Rochester, and Texas A&M University. Queen Mary University of London opened one of Europe's largest organ-on-chip facilities in February 2025 with funding from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Contract research organizations took 11.0% share at USD 23.7 Million, recording the fastest CAGR among end users as CRO-pharma partnerships such as Pharmaron-CN Bio scale standardized OOC service offerings. Cosmetics and other end users took 2.0% share, anchored by L'Oréal's investments in skin-chip platforms.
Regional Analysis
The Organ-on-a-Chip Market is heavily concentrated in North America and Europe, which together accounted for 72.0% of revenue in 2025. Asia Pacific is the fastest-growing region as China, Japan, South Korea, and Singapore scale public investment, while Latin America and the Middle East and Africa remain emerging adoption pockets.
North America
North America held the largest share of the Organ-on-a-Chip Market at 45.0% in 2025, generating USD 96.98 Million in revenue. The United States contributed the majority of regional revenue at approximately USD 92.5 Million, with Canada at USD 3.2 Million and Mexico at USD 1.3 Million. Demand is driven by the FDA Modernization Acts 2.0 and 3.0, the FDA April 2025 animal-testing roadmap, and the NIH TraCe MPS program. Emulate (Boston) and Hesperos (Orlando) anchor the domestic vendor base. The Wyss Institute at Harvard received an FDA partial option in 2023 to develop organ-chips for radiation countermeasures, illustrating cross-agency procurement appetite. In April 2025, the FDA explicitly committed to phasing out routine animal studies starting with monoclonal antibodies.
Europe
Europe captured 27.0% of the Organ-on-a-Chip Market in 2025, valued at USD 58.2 Million. Germany, the United Kingdom, the Netherlands, and France lead European demand. The Dutch Centre for Animal-Free Biomedical Translation (CPBT), funded with EUR 124 Million through the Dutch National Growth Fund, anchors regional capital flow, with MIMETAS as a primary partner. The European Medicines Agency continues to advance the 3R principles (replace, reduce, refine), and the EU UNLOOC project supported by Horizon Europe is advancing single-organ and multi-organ smart chip plates. In February 2025, Queen Mary University of London opened one of Europe's largest organ-on-chip facilities with NC3Rs funding.
Asia Pacific
Asia Pacific held a 22.0% share of the Organ-on-a-Chip Market in 2025, generating USD 47.4 Million in revenue, and is forecast to record a CAGR exceeding 36.0% through 2034. China leads regional demand with USD 22 Million in 2025, anchored by the November 2024 release of GB/T 44831-2024, the world's first national skin-on-a-chip standard, drafted by Southeast University's team led by Professor Gu Zhongze. Japan and South Korea are advancing iPSC-derived organ models; POSTECH researchers in South Korea launched 3D-bioprinted alveolar constructs that have drawn vaccine-maker funding. Singapore continues to host academic-industry consortia centered on tumor-on-chip oncology platforms.
Latin America
Latin America held a 3.5% share of the Organ-on-a-Chip Market in 2025, valued at USD 7.5 Million. Brazil and Mexico anchor regional demand through partnerships with global service providers and pharma CRO subcontractors. Adoption is concentrated in academic research and select cosmetics-industry toxicology testing. Regional growth is supported by increasing pharmaceutical R&D outsourcing from North America.
Middle East & Africa
Middle East and Africa accounted for 2.5% of the Organ-on-a-Chip Market in 2025, valued at USD 5.4 Million. The United Arab Emirates emerged as a regional leader after the Emirates Drug Establishment unveiled organ-on-chip technology at the World Health Expo (WHX) 2026 in Dubai in February 2026 under Project Falcon, an initiative combining lab automation, AI, and organ-chips for drug discovery. Israel-based Quris Technologies advanced its Bio-AI patient-on-chip platform after acquiring Nortis in October 2024. South Africa supports limited academic-led research in tropical disease modeling.
Country Analysis
The Organ-on-a-Chip Market is shaped at the country level by national regulatory posture, public R&D funding, and the concentration of domestic pharmaceutical and academic buyers. The United States leads, followed by China, Germany, and the United Kingdom.
United States
The United States Organ-on-a-Chip Market was valued at approximately USD 92.5 Million in 2025 and is projected to grow at a CAGR of 33.1% through 2034. Federal regulatory action drives demand: the FDA April 2025 roadmap, the FDA ISTAND Pilot Program (which admitted Emulate's Liver-Chip S1 in September 2024 as the first qualified organ-chip), the National Institutes of Health TraCe MPS centers funded with USD 31 Million across five years, and NIH's July 2025 prohibition on animal-only-study funding. The National Institute of Standards and Technology (NIST) is concurrently working with international researchers to standardize OOC engineering. Emulate's launch of AVA in June 2025 and Quris-AI's October 2024 acquisition of Nortis are anchor commercial events. Drug discovery applications captured roughly 63% of US Organ-on-a-Chip Market revenue in 2025.
China
The China Organ-on-a-Chip Market generated USD 22 Million in 2025 and is forecast to record a country CAGR of approximately 36.0% through 2034. China's release of GB/T 44831-2024, the country's first national standard for organ-on-chip technology covering skin chips, in November 2024 set a regulated procurement channel for cosmetics, drug screening, and toxicology testing. Southeast University, Boao Bio Group, and 19 other organizations co-drafted the standard. Government funding from the National Natural Science Foundation of China and aggressive academic-industry collaboration drive Chinese vendors to scale commercial OOC products for both domestic pharmaceutical procurement and export to Southeast Asia.
Germany
Germany generated USD 14.6 Million in Organ-on-a-Chip Market revenue in 2025 and is forecast to grow at a country CAGR of 31.0% through 2034. TissUse GmbH (Berlin) anchors the domestic vendor ecosystem with HUMIMIC multi-organ chip patents in 20 jurisdictions. Dynamic42, also based in Germany, formed a strategic collaboration in 2026 with Experimental Pharmacology and Oncology (EPO) to advance preclinical glioblastoma drug development using organ-chips. The Federal Ministry of Education and Research (BMBF) continues to fund 3R-aligned research consortia, and German pharmaceutical companies including Bayer and Boehringer Ingelheim are increasing organ-chip procurement in early-stage discovery workflows.
United Kingdom
The United Kingdom Organ-on-a-Chip Market reached USD 11.2 Million in 2025 and is forecast to expand at a CAGR of 32.0% through 2034. CN Bio Innovations (Cambridge) anchors UK leadership; the company's PhysioMimix technology is deployed by 16 of the leading global pharmaceutical firms according to its October 2025 launch disclosure. The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) funded the February 2025 opening of one of Europe's largest organ-on-chip facilities at Queen Mary University of London. The UK Engineering and Physical Sciences Research Council (EPSRC) issued a GBP 7 Million grant in March 2024 to establish a Centre for Doctoral Training focused on Organ-on-a-Chip technologies, building the next-decade scientist pipeline.
Organ-on-a-Chip Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
33.4%
The Forecast Market
Size for 2034 in USD:
$USD 2,890 M
Get more details on this report -
Key Market Segments
By Offering
- Organ-on-a-Chip Devices
- Consumables and Reagents
- Software and Data Analytics Solutions
- Microfluidic Platforms
- Cell Culture Media and Biomaterials
- Sensors and Monitoring Systems
- Laboratory Services
- Research and Development Services
- Others
By Organ Type
- Liver-on-a-Chip
- Lung-on-a-Chip
- Heart-on-a-Chip
- Kidney-on-a-Chip
- Brain-on-a-Chip
- Gut-on-a-Chip
- Skin-on-a-Chip
- Blood Vessel-on-a-Chip
- Tumor-on-a-Chip
- Multi-Organ-on-a-Chip
- Others
By Application
- Drug Discovery and Development
- Toxicity Testing
- Disease Modeling
- Personalized Medicine
- Cancer Research
- Regenerative Medicine
- Stem Cell Research
- Pharmacokinetic and Pharmacodynamic (PK/PD) Studies
- Precision Medicine Research
- Cosmetic Testing
- Chemical Safety Assessment
- Others
By End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Hospitals and Diagnostic Centers
- Government Research Organizations
- Medical Device Companies
- Cosmetic and Personal Care Companies
- Food and Beverage Industry
- Regulatory Agencies
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 215.5 M |
| Forecast Revenue (2034) | USD 2,890 M |
| CAGR (2025-2034) | 33.4% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Offering, (Organ-on-a-Chip Devices, Consumables and Reagents, Software and Data Analytics Solutions, Microfluidic Platforms, Cell Culture Media and Biomaterials, Sensors and Monitoring Systems, Laboratory Services, Research and Development Services, Others), By Organ Type, (Liver-on-a-Chip, Lung-on-a-Chip, Heart-on-a-Chip, Kidney-on-a-Chip, Brain-on-a-Chip, Gut-on-a-Chip, Skin-on-a-Chip, Blood Vessel-on-a-Chip, Tumor-on-a-Chip, Multi-Organ-on-a-Chip, Others), By Application, (Drug Discovery and Development, Toxicity Testing, Disease Modeling, Personalized Medicine, Cancer Research, Regenerative Medicine, Stem Cell Research, Pharmacokinetic and Pharmacodynamic (PK/PD) Studies, Precision Medicine Research, Cosmetic Testing, Chemical Safety Assessment, Others), By End User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Centers, Government Research Organizations, Medical Device Companies, Cosmetic and Personal Care Companies, Food and Beverage Industry, Regulatory Agencies, Others) |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | EMULATE, INC., MIMETAS B.V., CN BIO INNOVATIONS LTD, TISSUSE GMBH, INSPHERO AG, HESPEROS, INC., AXOSIM, INC., BICO GROUP AB, ALVEOLIX AG, QURIS TECHNOLOGIES LTD, NORTIS, INC., BIOMIMX S.R.L., BEONCHIP S.L., SYNVIVO, INC., NETRI, DYNAMIC42 GMBH, FLUIGENT, OBATALA SCIENCES, INC., THE CHARLES STARK DRAPER LABORATORY, INC., Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Organ-on-a-Chip Market?
The Global Organ-on-a-Chip Market was valued at USD 168.0 Million in 2024 and USD 215.5 Million in 2025, and is projected to reach USD 2,890 Million by 2034, growing at a CAGR of 33.4% from 2026 to 2034. Market growth is driven by drug discovery, precision medicine, microfluidics, and alternatives to animal testing.
Who are the major players in the Organ-on-a-Chip Market?
EMULATE, INC., MIMETAS B.V., CN BIO INNOVATIONS LTD, TISSUSE GMBH, INSPHERO AG, HESPEROS, INC., AXOSIM, INC., BICO GROUP AB, ALVEOLIX AG, QURIS TECHNOLOGIES LTD, NORTIS, INC., BIOMIMX S.R.L., BEONCHIP S.L., SYNVIVO, INC., NETRI, DYNAMIC42 GMBH, FLUIGENT, OBATALA SCIENCES, INC., THE CHARLES STARK DRAPER LABORATORY, INC., Others
Which segments covered the Organ-on-a-Chip Market?
By Offering, (Organ-on-a-Chip Devices, Consumables and Reagents, Software and Data Analytics Solutions, Microfluidic Platforms, Cell Culture Media and Biomaterials, Sensors and Monitoring Systems, Laboratory Services, Research and Development Services, Others), By Organ Type, (Liver-on-a-Chip, Lung-on-a-Chip, Heart-on-a-Chip, Kidney-on-a-Chip, Brain-on-a-Chip, Gut-on-a-Chip, Skin-on-a-Chip, Blood Vessel-on-a-Chip, Tumor-on-a-Chip, Multi-Organ-on-a-Chip, Others), By Application, (Drug Discovery and Development, Toxicity Testing, Disease Modeling, Personalized Medicine, Cancer Research, Regenerative Medicine, Stem Cell Research, Pharmacokinetic and Pharmacodynamic (PK/PD) Studies, Precision Medicine Research, Cosmetic Testing, Chemical Safety Assessment, Others), By End User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Centers, Government Research Organizations, Medical Device Companies, Cosmetic and Personal Care Companies, Food and Beverage Industry, Regulatory Agencies, Others)
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date